Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study

J Natl Cancer Inst. 2000 Nov 1;92(21):1764-72. doi: 10.1093/jnci/92.21.1764.

Abstract

Background: Only a fraction of cigarette smokers develop lung cancer, suggesting that people differ in their susceptibility to this disease. We investigated whether differences in DNA repair capacity (DRC) for repairing tobacco carcinogen-induced DNA damage are associated with differential susceptibility to lung cancer.

Methods: From August 1, 1995, through April 30, 1999, we conducted a hospital-based, case-control study of 316 newly diagnosed lung cancer patients and 316 cancer-free control subjects matched on age, sex, and smoking status. DRC was measured in cultured lymphocytes with the use of the host-cell reactivation assay with a reporter gene damaged by a known activated tobacco carcinogen, benzo[a]pyrene diol epoxide. Statistical tests were two-sided.

Results: Overall, lower DRC was observed in case patients than in control subjects (P:<.001) and was associated with a greater than twofold increased risk of lung cancer. Compared with the highest DRC quartile in the control subjects and after adjustment for age, sex, pack-years of smoking, family history of cancer, and other covariates, reduced DRC was associated with increased risk of lung cancer in a dose-dependent fashion (odds ratio [OR] = 1.8 with 95% confidence interval [CI] = 1.1-3.1, OR = 2.0 with 95% CI = 1.2-3.4, and OR = 4. 3 with 95% CI = 2.6-7.2 for the second, third, and fourth quartiles, respectively; P:(trend)<.001). Case patients who were younger at diagnosis (<60 years old), female, or lighter smokers or who reported a family history of cancer exhibited the lowest DRC and the highest lung cancer risk among their subgroups, suggesting that these subgroups may be especially susceptible to lung cancer.

Conclusion: The results provide evidence that low DRC is associated with increased risk of lung cancer. The findings from this hospital-based, case-control study should be validated in prospective studies.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Age Factors
  • Aged
  • Carcinogens / adverse effects*
  • Case-Control Studies
  • Cell Line
  • DNA Adducts / drug effects
  • DNA Adducts / genetics*
  • DNA Repair / drug effects
  • DNA Repair / genetics*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Logistic Models
  • Lung Neoplasms / epidemiology
  • Lung Neoplasms / etiology*
  • Lung Neoplasms / genetics
  • Lymphocytes
  • Male
  • Middle Aged
  • Plasmids
  • Sex Factors
  • Smoking / adverse effects*
  • Texas / epidemiology
  • Transfection

Substances

  • Carcinogens
  • DNA Adducts